CAJ | 학술논문

近年来,干细胞移植用于治疗缺血性卒中成为研究热点.然而,由于胚胎干细胞(embryonic stem cell,ESC)移植受到伦理和法律的限制,干细胞研究一度陷入困境.诱导多能干细胞(induced pluripotent stem cell,iPSC)是通过将特定的转录因子导入体细胞而产生的一类细胞,其具有与ESC相似的特征,而且回避了伦理问题和免疫排斥反应,使得其成为最理想的ESC替代者.尽管目前关于iPSC的研究已取得一定的进展,但其诱导效率和安全性问题仍有待解决.文章就iPSC移植治疗缺血性卒中的现状、机制及其在临床应用中面临的问题进行了综述.
근년래,간세포이식용우치료결혈성졸중성위연구열점.연이,유우배태간세포(embryonic stem cell,ESC)이식수도윤리화법률적한제,간세포연구일도함입곤경.유도다능간세포(induced pluripotent stem cell,iPSC)시통과장특정적전록인자도입체세포이산생적일류세포,기구유여ESC상사적특정,이차회피료윤리문제화면역배척반응,사득기성위최이상적ESC체대자.진관목전관우iPSC적연구이취득일정적진전,단기유도효솔화안전성문제잉유대해결.문장취iPSC이식치료결혈성졸중적현상、궤제급기재림상응용중면림적문제진행료종술.
In recent years,stem cell transplantation for the treatment of ischemic stroke has become a hot topic.However,since embryonic stem cells (ESCs) transplantation is limited by the ethics and law,stem cell research was once in trouble.Induced pluripotent stem cells (iPSCs) are a class of cells by introducing the specific transcription factors into somatic cells,which have the similar characteristics with ESCs,and also avoid the ethical issues and immunological rejection,making them become the most ideal replacer of ESCs.Although the current research on iPSCs has made some progress,their induction efficiency and safety issues remain to be resolved.This article reviews the status quo,mechanisms,and problems faced in clinical practice for iPSCs transplantation in the treatment of ischemic stroke.